Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma

Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma

Background To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of eftilagimod alpha (efti), a soluble lymphocyte activation gene-3 protein, in combination with the programmed cell death-1 (PD-1) antagonist pembrolizumab.Methods The study was divided into two parts; parts A an...

Full description

Saved in:

Bibliographic Details
Main Authors:	Christian Mueller, Andrew Haydon, Victoria Atkinson, Prashanth Prithviraj, Frederic Triebel, Chrystelle Brignone, Adnan Khattak, Melissa Eastgate, Amitesh Roy
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-10-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/8/2/e001681.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma
by: Dimo Dietrich, et al.
Published: (2020-05-01)

LAG-3: from molecular functions to clinical applications
by: Takumi Maruhashi, et al.
Published: (2020-10-01)

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
by: Tuba N. Gide, et al.
Published: (2023-12-01)

Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party
by: Chenyu Lu, et al.
Published: (2024-03-01)

Deciphering LAG-3: unveiling molecular mechanisms and clinical advancements
by: Alejandra Martínez-Pérez, et al.
Published: (2024-10-01)

Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC: Real-world evidence
by: Irina Surovtsova, et al.
Published: (2025-12-01)

Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3
by: Emma Jones, et al.
Published: (2020-10-01)

LAG3 immune inhibitors: a novel strategy for melanoma treatment
by: Renzheng Wu, et al.
Published: (2024-12-01)

Correction: Deciphering LAG-3: unveiling molecular mechanisms and clinical advancements
by: Alejandra Martínez-Pérez, et al.
Published: (2024-11-01)

Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma
by: Ramses Sadek, et al.
Published: (2021-06-01)

LAG3 is not expressed in human and murine neurons and does not modulate α‐synucleinopathies
by: Marc Emmenegger, et al.
Published: (2021-07-01)

Solubility of Structurally Complicated Materials: 3. Hair
by: Ari L. Horvath
Published: (2009-01-01)

Structural bioinformatic study of human mitochondrial respiratory integral membrane megacomplex and its AlphaFold 3 predicted water-soluble QTY megacomplex analog
by: Edward Chen, et al.

Efficacy of pembrolizumab plus lenvatinib as first‐line treatment for metastatic renal cell carcinoma with multiple brain metastases
by: Daisuke Matsumoto, et al.
Published: (2025-01-01)

Significant response to pembrolizumab plus lenvatinib in Epstein–Barr-virus-associated intrahepatic cholangiocarcinoma: a case report
by: Lisha Li, et al.
Published: (2024-12-01)

Impact of corticosteroids on the efficacy of first-line pembrolizumab plus chemotherapy in patients with advanced non-small-cell lung cancer
by: Amytis Roboubi, et al.
Published: (2025-02-01)

Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis
by: Youwen Zhu, et al.
Published: (2025-01-01)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in the Chinese healthcare system
by: Wenwang Lang, et al.
Published: (2025-01-01)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
by: Xiaohui Zeng, et al.
Published: (2019-12-01)

Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial
by: Gang Chen, et al.
Published: (2025-02-01)

PD-1 and LAG-3 dual blockade: emerging mechanisms and potential therapeutic prospects in cancer
by: Xiangyu Qiu, et al.
Published: (2024-11-01)

Editorial Comment on “Efficacy of pembrolizumab plus lenvatinib as first‐line treatment for metastatic renal cell carcinoma with multiple brain metastases”
by: Manabu Kato
Published: (2025-01-01)

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
by: Antoni Ribas, et al.
Published: (2020-10-01)

Long-Term Temporal Trends of Real-World Healthcare Costs Associated with Nivolumab Plus Ipilimumab and Pembrolizumab Plus Axitinib as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma
by: Ella Xiaoyan Du, et al.
Published: (2024-08-01)

Solid-State Modification Strategies for Alpha-Mangostin Solubility Enhancement: A Review on Recent Progress
by: Nurin Syamimi Ahmad Izuren Shah, et al.
Published: (2025-01-01)

Comparison of lenvatinib plus pembrolizumab versus first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a real-world retrospective study
by: Zhenyun Yang, et al.
Published: (2024-11-01)

Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors
by: Alfred Zippelius, et al.
Published: (2022-11-01)

Structural bioinformatic study of six human olfactory receptors and their AlphaFold3 predicted water-soluble QTY variants and OR1A2 with an odorant octanoate and TAAR9 with spermidine
by: Finn Johnsson, et al.
Published: (2025-01-01)

Hölder estimate for the 3 point-vortex problem with alpha-models
by: Godard-Cadillac, Ludovic
Published: (2023-01-01)

AlphaFold 2, but not AlphaFold 3, predicts confident but unrealistic β-solenoid structures for repeat proteins
by: Olivia S. Pratt, et al.
Published: (2025-01-01)

Anti-TNF-Alpha-Adalimumab Therapy Had Time Lag of Improvement in Synovial Hypertrophy Compared to Rapid Response in Power Doppler Synovial Vascularity
by: Ying-Chou Chen, et al.
Published: (2017-01-01)

A real-world drug safety surveillance study from the FAERS database of hepatocellular carcinoma patients receiving pembrolizumab alone and plus lenvatinib
by: Huaxiang Wang, et al.
Published: (2025-01-01)

Unanchored simulated treatment comparison on survival outcomes using parametric and Royston-Parmar models with application to lenvatinib plus pembrolizumab in renal cell carcinoma
by: Christopher G. Fawsitt, et al.
Published: (2025-01-01)

Noninvasive Immunotyping and Immunotherapy Monitoring of Lung Cancers via Nuclear Imaging of LAG‐3 and PD‐L1
by: Lishu Zhao, et al.
Published: (2025-01-01)

Study on the Lagging Support Mechanism of Anchor Cable in Coal Roadway Based on FLAC3D Modified Model
by: Xiangyu Wang, et al.
Published: (2021-01-01)

Unlocking therapeutic potential: Targeting lymphocyte activation Gene-3 (LAG-3) with fibrinogen-like protein 1 (FGL1) in systemic lupus erythematosus
by: Bing Wang, et al.
Published: (2024-12-01)

Solubility of CO2 in molten Li2Co3-LiCl
by: Hu X.-W., et al.
Published: (2021-01-01)

Pembrolizumab plus Pemetrexed and Platinum in Metastatic Non-Squamous Non-Small Cell Lung Cancer: A Real-Life Study at a Portuguese Centre
by: Maria João Santos, et al.
Published: (2025-02-01)

20588. VARIANTES COMUNES DE LOS GENES LAG3/CD4 Y RIESGO PARA TEMBLOR ESENCIAL
by: F. Jiménez Jiménez, et al.
Published: (2024-11-01)

Role of immune-checkpoint LAG3 as a biomarker finding tool in patient-derived organoid cultures of breast cancer
by: Barbara Carrese, et al.
Published: (2024-12-01)